middle.news
Radiopharm Theranostics Advances RV-01 Trial with 70 mCi Dose in Solid Tumors
8:59am on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Advances RV-01 Trial with 70 mCi Dose in Solid Tumors
8:59am on Wednesday 26th of August, 2026 AEST
Key Points
First patient dosed at 70 mCi RV-01 dose
Phase 1/2a trial focuses on safety and anti-tumor activity
RV-01 targets B7-H3 immune checkpoint in multiple cancers
Joint venture with MD Anderson Cancer Center
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE